Schrum Private Wealth Management LLC Boosts Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Schrum Private Wealth Management LLC lifted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.6% during the 3rd quarter, Holdings Channel reports. The firm owned 2,738 shares of the medical equipment provider’s stock after acquiring an additional 169 shares during the period. Schrum Private Wealth Management LLC’s holdings in Intuitive Surgical were worth $1,345,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of ISRG. Hazlett Burt & Watson Inc. grew its holdings in shares of Intuitive Surgical by 5.8% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 362 shares of the medical equipment provider’s stock worth $177,000 after acquiring an additional 20 shares during the period. Mitchell Mcleod Pugh & Williams Inc. boosted its stake in Intuitive Surgical by 4.1% during the 3rd quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 503 shares of the medical equipment provider’s stock valued at $247,000 after purchasing an additional 20 shares during the last quarter. Ullmann Wealth Partners Group LLC increased its holdings in Intuitive Surgical by 1.6% in the 3rd quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider’s stock worth $653,000 after buying an additional 21 shares in the last quarter. One Wealth Management Investment & Advisory Services LLC grew its stake in shares of Intuitive Surgical by 3.4% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock worth $310,000 after acquiring an additional 23 shares during the period. Finally, Falcon Wealth Planning grew its position in Intuitive Surgical by 0.4% in the 3rd quarter. Falcon Wealth Planning now owns 5,693 shares of the medical equipment provider’s stock worth $2,797,000 after purchasing an additional 23 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ISRG shares. The Goldman Sachs Group set a $604.00 price target on Intuitive Surgical in a research note on Friday, October 18th. BTIG Research set a $535.00 price target on Intuitive Surgical in a report on Friday, October 18th. Truist Financial boosted their target price on shares of Intuitive Surgical from $520.00 to $570.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Oppenheimer restated a “market perform” rating on shares of Intuitive Surgical in a report on Friday, October 18th. Finally, Mizuho increased their price objective on shares of Intuitive Surgical from $440.00 to $500.00 in a research report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $513.74.

Intuitive Surgical Trading Down 0.1 %

Shares of Intuitive Surgical stock traded down $0.54 on Wednesday, hitting $536.53. 195,670 shares of the company traded hands, compared to its average volume of 1,453,816. Intuitive Surgical, Inc. has a 52 week low of $287.98 and a 52 week high of $542.59. The company has a market cap of $191.10 billion, a PE ratio of 86.35, a PEG ratio of 5.27 and a beta of 1.39. The stock’s 50 day moving average price is $495.85 and its 200-day moving average price is $455.08.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The firm had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.01 billion. As a group, research analysts anticipate that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

Insider Activity

In other news, EVP Robert Desantis sold 396 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $486.88, for a total transaction of $192,804.48. Following the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,680,761.28. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Robert Desantis sold 396 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $486.88, for a total transaction of $192,804.48. Following the completion of the sale, the executive vice president now directly owns 5,506 shares in the company, valued at $2,680,761.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Henry L. Charlton sold 40,243 shares of Intuitive Surgical stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the completion of the transaction, the senior vice president now owns 3,001 shares in the company, valued at $1,461,006.84. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 91,178 shares of company stock worth $45,897,071. 0.80% of the stock is currently owned by corporate insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.